Big Retailers Could Shy Away From CBD as FDA’s Unease Grows
- Wholesalers should ‘have big concerns,’ Green Growth CEO says
- Jefferies analyst sees 2022 retail sales of just $3.5 billion
This article is for subscribers only.
CBD wholesalers should “have big concerns” about the U.S. Food and Drug Administration’s growing unease about the safety of the cannabis compound, according to one chief executive officer.
The FDA said Monday that it “cannot conclude that CBD is generally recognized as safe among qualified experts for its use in human or animal food.”